Chronic systemic inflammation in the pathogenesis of comorbid pathology and it's correction.
Introduction: The paper presents the findings of our own study on the changes of the systemic inflammation in patients with type 2 diabetes mellitus (DM2) and ischemic heart disease (IHD) during the combination treatment with metformin and pioglitazone. The aim of the paper is to define the dynamics of the systemic inflammation in patients with type 2 diabetes mellitus and ischemic heart disease in combination treatment with metformin and pioglitazone. Meterials and methods: 95 patients with IHD concomitant with DM2 have been treated. Patients, enrolled into study, have been randomized into 2 groups: the comparison group (n=37) treated with metformin andsulphonylureas, and the study group (n=58) treated with metformin and pioglitazone. The proposed course of therapy lasted 6 months. Results and conclusions: Before, after 3 and 6 months of treatment the control over the state of inflammatory responses was made and C-reactive protein, tumor necrosis factor-alpha, Interleukin-6 was assessed. The resulting data confirmed a statistically significant reduction under the effect of the combined treatment with the proposed combination of marker drugs and the degree of chronic systemic inflammation that is specific for IHD and DM2, which has a positive impact on the development and progress of IHD in DM2 patients, is well tolerated and can be considered as a pathogenic factor in the therapy of the presented comorbid nosologies.